Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kane Biotech has entered into an agreement to develop an antibiofilm-antimicrobial wound gel formulation for the US Army Institute of Surgical Research (USAISR).
Subscribe to our email newsletter
Under the cooperative research and development agreement (CRADA), the company will test the efficacy of the wound gel containing antimicrobial peptide KSL-W and DispersinB antibiofilm enzyme in killing biofilm embedded bacteria .
The objective of the CRADA is to address the needs of the United States Army Dental and Trauma Research Detachment’s (USADTRD) programs, whose mission is to provide military relevant research and solutions to treat and rehabilitate craniomaxillofacial trauma and prevent infectious disease.
The USADTRD’s biofilm impaired wound healing program mainly focuses on providing algorithms to understand biofilm pathophysiology and test agents useful to treat not only dental biofilm and combat wounds-associated biofilm infections, but also to provide antimicrobials for the control of dental plaque-associated oral infection.